Could targeting a bacterial protein help overcome chemotherapy resistance? Dr Rahul Gupta reveals how predictive AI could identify the most promising drug candidates before they reach the laboratory.
Researchers have discovered how dormant pancreatic cancer cells manipulate their surroundings to evade CAR T-cell therapy, identifying a potential therapeutic target for overcoming treatment resistance.
Protein damage could provide a valuable readout for evaluating potential anti-ageing therapies, but reducing complex biological responses to a single score raises important questions about interpretation and validation.
The PsychAD Consortium is using human genetics, single-cell genomics and automated screening to pinpoint potential drug targets for Alzheimer’s disease and investigate their therapeutic potential.
A landmark package of UK-EU agreements announced at the Brussels Summit covers trade barriers, workforce mobility and health security cooperation, with potential knock-on effects for the life sciences sector.
Penn State researchers have developed a light-activated nanoparticle system capable of delivering cancer-targeting microRNA directly to tumours.
A new study has revealed how the protein galectin-3 directly modifies amyloid fibril structure and drives microglial inflammation in Alzheimer’s disease.
Patients with multiple myeloma who develop a rare but life-threatening gastrointestinal complication following CAR T cell therapy show more than 100 times the average level of long-term CAR T-cell persistence in their bloodstream, MD Anderson researchers report.
Laboratory automation in drug discovery can increase the number of compounds teams screen. But how do researchers decide which results are worth following up? In Lab Automation 2026, six researchers and industry specialists share practical lessons on validating screening hits, improving reproducibility in complex cell assays and deciding where automation can make the greatest difference.
Poor recovery, inconsistent growth and changes in morphology can affect organoid research. How much experimental variability starts with the culture itself?
How can multiomics help researchers identify more promising drug targets? Dr Shi-qi An explores how combining molecular data can reveal therapeutic vulnerabilities and mechanisms of drug resistance.